LOW-DOSE KETOCONAZOLE IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS (HRPC): A SINGLE INSTITUTION EXPERIENCE

被引：0
|
作者：
Romero, J. [1 ]
Rodriguez, A. [1 ,2 ]
Villacampa, F. [1 ]
Duarte, J. M. [1 ]
Cabrera, F. [1 ]
Blanco, M. [1 ]
Sepulveda, J. [2 ]
Rodriguez, A. [1 ,2 ]
Castellano, D. [2 ]
Leiva, O. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Dept Urol, Madrid, Spain
[2] Hosp Univ 12 Octubre, Dept Oncol, Madrid, Spain
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2009年 / 8卷 / 04期
关键词：
D O I：
10.1016/S1569-9056(09)60056-7
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [31] NAVELBIN AS A SECOND LINE TREATMENT FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER (HRPC)
    Jana, J. K.
    Rovny, A. R.
    Divisova, K. D.
    Filipensky, P. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 658 - 659
  • [32] Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer
    Orlando, M
    Chacón, M
    Salum, G
    Chacón, DR
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 177 - 181
  • [33] Cyclosporine and low-dose ketoconazole in renal transplant recipients: A single center experience
    Carbajal, H
    Soltero, L
    Rodriguez-Montalvo, C
    Valdes, A
    TRANSPLANTATION, 2005, 79 (02) : 252 - 253
  • [34] Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC).
    Nelius, T.
    Klatte, T.
    Reiher, F.
    Filleur, S.
    Yap, R.
    Allhoff, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 254S - 254S
  • [35] Experience with docetaxel in hormone-refractory prostate cancer (HRPC) at three Australian cancer centers: A retrospective study
    Hovey, Elizabeth
    Gabriel, Gabriel
    George, Monika
    Shapiro, Jeremy
    Chern, Boris
    Moylan, Eugene
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2007, 3 (03) : 156 - 162
  • [36] Randomised study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [37] Hormone refractory prostate cancer (HRPC): Present and future approaches of therapy
    Di Lorenzo, G
    De Placido, S
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2006, 19 (01) : 11 - 33
  • [38] A retrospective analysis on 35 patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel
    Carlini, P.
    Felici, A.
    Ruggeri, E. M.
    Moscetti, L.
    Chilelli, M.
    Ciccarese, M.
    Pino, M. S.
    Cecere, F. L.
    Nuzzo, C.
    Sperduti, I
    Pollera, C. F.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [39] Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC).
    Stoss, O.
    Albers, P.
    Werther, M.
    Zielinsky, D.
    Jost, N.
    Rueschoff, J.
    Henkel, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 251S - 251S
  • [40] Experience with docetaxel in hormone-refractory prostate cancer (HRPC) at three Australian cancer centers: A retrospective study.
    Hovey, EJ
    George, M
    Gabriel, GS
    Shapiro, J
    Chern, B
    Moylan, EJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 449S - 449S
12345